

AMENDMENTS TO THE CLAIMS

1. (Currently amended) A process for the preparation of a composite containing a drug dispersed in an organic carrier, ~~wherein the drug is massively dispersed (in bulk) within the particles of said organic carrier and it is present in amorphous form in a quantity greater than or equal to 50%; comprising the following steps:~~

a) ~~forming a mixture of~~ mixing a drug with an and a particulate organic carrier selected from the group consisting of water-soluble complexing agents ~~chosen from cyclodextrins and maltodextrins~~, water-insoluble cross-linked polymers, and mixtures thereof;

b) ~~irradiating applying an oscillating electromagnetic field to the mixture obtained in a), with microwaves~~, wherein the oscillating electromagnetic field is microwave irradiation ~~microwave power is modulated so that to increase the temperature of the mixture increases until it reaches a value higher to a temperature greater than the melting temperature of the drug and it is then maintained constant at the temperature greater than the melting temperature of the drug said value for at least 5 minutes to provide a composite containing the drug dispersed within the particulate organic carrier deposited both on the surfaces and inside the organic carrier particles, wherein the drug is present in the composite in amorphous form in a quantity greater than or equal to 50% by weight based on the total amount of the drug.~~

2. (Currently amended) ~~Process according to The process of claim 1, wherein in step a) a wet mixture is formed by~~ mixing a drug and a particulate organic carrier further comprises adding a solvent to provide a wet mixture.

3. (Currently amended) ~~Process according to The process of claim 2, wherein said solvent is water.~~

4. (Currently amended) The process ~~according to of~~ claim 3, ~~in which wherein~~ said wet mixture is formed by adding water to the ~~carrier-drug composite~~ drug and particulate organic carrier in a quantity ~~comprised of~~ between 0.1 ml/g and 5 ml/g ~~with respect to the dry mixture of the composite based on the weight of drug and particulate organic carrier.~~

5. (Currently amended) The process ~~according to of~~ claim 2, ~~in which wherein the~~ oscillating electromagnetic field is applied to the mixture at a the pressure at ~~which the~~ irradiation is ~~carried out is comprised of~~ between 1 and 20 bar.

6. (Currently amended) ~~A process according to~~ The process of claim 1, wherein ~~step b) the oscillating electromagnetic field is applied to the mixture is carried out in a container constituted of comprising a dielectric material having coupling capacity with [[the]] microwaves.~~

7. (Currently amended) The process ~~according to of~~ claim 6, wherein said dielectric material is polytetrafluoroethylene loaded with graphite.

8. (Currently amended) The process ~~according to of~~ claim 1, ~~in which wherein the~~ microwave irradiation ~~with microwaves~~ is carried out with power in a ~~power the~~ range ~~comprised of~~ between 100 W and 5000 W, for ~~an overall a~~ time up to 120 minutes.

9. (Currently amended) ~~A process according to~~ The process of claim 1, wherein said cross-linked polymer is selected from the group consisting of cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethylcellulose, cross-linked starch, cross-linked dextran, cross-linked polystyrene and cross-linked β -cyclodextrin.

10. (Currently amended) ~~A process according to~~ The process of claim 1, wherein said drug is a drug sparingly soluble in water.

11-20. (Canceled)

21. (New) The process of claim 1, wherein said water-soluble complexing agents are selected from the group consisting of cyclodextrins, maltodextrins, and mixtures thereof.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{llc}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100